Search Results

Bionano Genomics, Inc. announced the Company’s robust participation at two upcoming cytogenetics conferences.

Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc., announced the editorial panel of the American Medical Association established a new Category I Current Procedural Terminology code for the use of optical genome mapping in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies.

Bionano Genomics, Inc. announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the RBC Capital Markets 2024 Global Healthcare Conference on May 15, 2024.

Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano’s VIA™ software to Revvity’s next generation sequencing (NGS) customers as part of its newborn sequencing research workflow.

Bionano Genomics, Inc. reported financial results for the first quarter ended March 31, 2024.

Bionano Genomics Inc. announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026.

Bionano Genomics today announced the publication of three studies which collectively illustrate the continued development of data supporting the utility of optical genome mapping (OGM) in cell and gene therapy applications.

Bionano Genomics, Inc. announced significant upgrades to its suite of computational tools for comprehensive cancer analysis.

Bionano Genomics, Inc. announced the publication of a study from Penn State College of Medicine that used optical genome mapping to search for clinically and biologically relevant genomic variations in pediatric B-cell acute lymphoblastic leukemia.

Bionano Genomics, Inc. announced the full commercial release of the Stratys™ system, the Company’s system for high throughput optical genome mapping.